Figure 4: Western blot for primary cell cultures derived from 6 patients with head and neck cancer. Patients #1, 2, and 5 demonstrated greater Sphk1 expression and had recurrence at 11, 8, and 5 months respectively. Patients #3, 4, and 6 showed lesser Sphk1 expression and had no recurrence at 11 months and beyond.